Nestlé India says infant-formula labels comply as FSSAI files three cases
Nestlé India has denied allegations around labels and a biotin test result for NAN Excella Pro and Lactogen Pro, saying the products comply with regulations. The clarification follows three FSSAI adjudication cases; shares closed 1.4% lower at ₹1,353.10.
What happened
Nestle India denied allegations tied to FSSAI action over infant-formula labels and a Biotin test result, saying NAN Excella Pro and Lactogen Pro comply with
Key facts
- 3 adjudication cases filed by FSSAI
- Stock closed 1.4% lower at ₹1,353.10
- Stock down 3% over one week
- Stock down 8% over one month
- Stock down 4% over four months
- Stock up 11.5% over six months
- Stock up 11% over one year
- Stock up 33% over five years
- 52-week range: ₹1,145.10–₹1,553
Why this matters
Treat infant nutrition as a higher-diligence segment for partnerships or acquisitions, prioritizing targets with robust FSSAI compliance records, label substantiation and testing controls.
What to watch
- FSSAI adjudication orders, hearing dates, penalties, corrective-action requirements or product withdrawal directions.
- Publication of disputed biotin test methodology, sample provenance, batch numbers and any independent retest results.
- Nestlé India disclosures on provisions, legal risk, label changes, inventory write-offs or sales impact.
- Modern-trade, pharmacy-chain and e-commerce actions on listings, stock acceptance and product warnings.
- Competitor price promotions, shelf-space gains and prescription/pharmacist recommendations in premium infant nutrition.
- Any broader FSSAI guidance on infant-formula labelling, nutrient tolerances or health claims.
- Audit all India infant-nutrition SKU labels, nutrient declarations, claim substantiation and batch-level laboratory records before further FSSAI action.
- Prepare SKU-specific relabelling, retailer communication and inventory-segregation plans for NAN Excella Pro and Lactogen Pro.
- Increase pediatrician, pharmacist and consumer-facing communication focused on product safety, regulatory compliance and preparation guidance.
- Monitor marketplace and pharmacy listings for voluntary delisting, altered search placement or competitor promotional activity.
- Build retailer contingency sourcing plans for infant formula substitutes if any affected SKUs face disruption.